nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Psychotic disorder—Dapsone—leprosy	0.0428	0.0428	CcSEcCtD
Lisdexamfetamine—Dyskinesia—Thalidomide—leprosy	0.0328	0.0328	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Thalidomide—leprosy	0.0265	0.0265	CcSEcCtD
Lisdexamfetamine—Vision blurred—Dapsone—leprosy	0.0248	0.0248	CcSEcCtD
Lisdexamfetamine—Libido decreased—Thalidomide—leprosy	0.0242	0.0242	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Thalidomide—leprosy	0.0236	0.0236	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Thalidomide—leprosy	0.0229	0.0229	CcSEcCtD
Lisdexamfetamine—Diplopia—Thalidomide—leprosy	0.0224	0.0224	CcSEcCtD
Lisdexamfetamine—Disturbance in sexual arousal—Thalidomide—leprosy	0.0222	0.0222	CcSEcCtD
Lisdexamfetamine—Affect lability—Thalidomide—leprosy	0.0221	0.0221	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Thalidomide—leprosy	0.0219	0.0219	CcSEcCtD
Lisdexamfetamine—Tachycardia—Dapsone—leprosy	0.021	0.021	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Thalidomide—leprosy	0.0202	0.0202	CcSEcCtD
Lisdexamfetamine—Insomnia—Dapsone—leprosy	0.0195	0.0195	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Thalidomide—leprosy	0.0178	0.0178	CcSEcCtD
Lisdexamfetamine—Weight increased—Thalidomide—leprosy	0.0176	0.0176	CcSEcCtD
Lisdexamfetamine—Weight decreased—Thalidomide—leprosy	0.0175	0.0175	CcSEcCtD
Lisdexamfetamine—Depression—Thalidomide—leprosy	0.0172	0.0172	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Thalidomide—leprosy	0.0171	0.0171	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Thalidomide—leprosy	0.017	0.017	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Dapsone—leprosy	0.017	0.017	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Thalidomide—leprosy	0.0169	0.0169	CcSEcCtD
Lisdexamfetamine—Hepatitis—Thalidomide—leprosy	0.0155	0.0155	CcSEcCtD
Lisdexamfetamine—Visual impairment—Thalidomide—leprosy	0.0149	0.0149	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Thalidomide—leprosy	0.0147	0.0147	CcSEcCtD
Lisdexamfetamine—Eye disorder—Thalidomide—leprosy	0.0145	0.0145	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Thalidomide—leprosy	0.0144	0.0144	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Thalidomide—leprosy	0.014	0.014	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Thalidomide—leprosy	0.014	0.014	CcSEcCtD
Lisdexamfetamine—Vomiting—Dapsone—leprosy	0.0137	0.0137	CcSEcCtD
Lisdexamfetamine—Mental disorder—Thalidomide—leprosy	0.0136	0.0136	CcSEcCtD
Lisdexamfetamine—Malnutrition—Thalidomide—leprosy	0.0135	0.0135	CcSEcCtD
Lisdexamfetamine—Headache—Dapsone—leprosy	0.0135	0.0135	CcSEcCtD
Lisdexamfetamine—Nervousness—Thalidomide—leprosy	0.0131	0.0131	CcSEcCtD
Lisdexamfetamine—Nausea—Dapsone—leprosy	0.0128	0.0128	CcSEcCtD
Lisdexamfetamine—Vision blurred—Thalidomide—leprosy	0.0127	0.0127	CcSEcCtD
Lisdexamfetamine—Tremor—Thalidomide—leprosy	0.0126	0.0126	CcSEcCtD
Lisdexamfetamine—Agitation—Thalidomide—leprosy	0.0124	0.0124	CcSEcCtD
Lisdexamfetamine—Angioedema—Thalidomide—leprosy	0.0123	0.0123	CcSEcCtD
Lisdexamfetamine—Palpitations—Thalidomide—leprosy	0.0119	0.0119	CcSEcCtD
Lisdexamfetamine—Convulsion—Thalidomide—leprosy	0.0117	0.0117	CcSEcCtD
Lisdexamfetamine—Hypertension—Thalidomide—leprosy	0.0117	0.0117	CcSEcCtD
Lisdexamfetamine—Anxiety—Thalidomide—leprosy	0.0114	0.0114	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Thalidomide—leprosy	0.0114	0.0114	CcSEcCtD
Lisdexamfetamine—Dry mouth—Thalidomide—leprosy	0.0112	0.0112	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Thalidomide—leprosy	0.0108	0.0108	CcSEcCtD
Lisdexamfetamine—Tachycardia—Thalidomide—leprosy	0.0107	0.0107	CcSEcCtD
Lisdexamfetamine—Skin disorder—Thalidomide—leprosy	0.0107	0.0107	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Thalidomide—leprosy	0.0106	0.0106	CcSEcCtD
Lisdexamfetamine—Anorexia—Thalidomide—leprosy	0.0105	0.0105	CcSEcCtD
Lisdexamfetamine—Insomnia—Thalidomide—leprosy	0.00996	0.00996	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Thalidomide—leprosy	0.00982	0.00982	CcSEcCtD
Lisdexamfetamine—Somnolence—Thalidomide—leprosy	0.00979	0.00979	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Thalidomide—leprosy	0.00969	0.00969	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Thalidomide—leprosy	0.00957	0.00957	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Thalidomide—leprosy	0.00951	0.00951	CcSEcCtD
Lisdexamfetamine—Fatigue—Thalidomide—leprosy	0.0095	0.0095	CcSEcCtD
Lisdexamfetamine—Constipation—Thalidomide—leprosy	0.00942	0.00942	CcSEcCtD
Lisdexamfetamine—Urticaria—Thalidomide—leprosy	0.00875	0.00875	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Thalidomide—leprosy	0.00871	0.00871	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Thalidomide—leprosy	0.00811	0.00811	CcSEcCtD
Lisdexamfetamine—Asthenia—Thalidomide—leprosy	0.0079	0.0079	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Thalidomide—leprosy	0.00754	0.00754	CcSEcCtD
Lisdexamfetamine—Dizziness—Thalidomide—leprosy	0.00728	0.00728	CcSEcCtD
Lisdexamfetamine—Vomiting—Thalidomide—leprosy	0.007	0.007	CcSEcCtD
Lisdexamfetamine—Rash—Thalidomide—leprosy	0.00694	0.00694	CcSEcCtD
Lisdexamfetamine—Dermatitis—Thalidomide—leprosy	0.00694	0.00694	CcSEcCtD
Lisdexamfetamine—Headache—Thalidomide—leprosy	0.0069	0.0069	CcSEcCtD
Lisdexamfetamine—Nausea—Thalidomide—leprosy	0.00654	0.00654	CcSEcCtD
